Free tool
FAERS Monitor: Primaxin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050587 or its brand name (Primaxin, Cilastatin Sodium, Imipenem). Reports on generic versions are filed under their own applications.
Reports
2,371
Serious
1,943
82% of reports
Hospitalization
1,063
Death reported
560
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product use in unapproved indication221
- convulsion188
- drug ineffective127
- pyrexia122
- pneumonia116
- off label use115
- sepsis103
- death91
- renal failure74
- septic shock74
- multi-organ failure72
- rash72
- thrombocytopenia72
- nausea60
- respiratory failure59
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 193 |
| 2005 | 202 |
| 2006 | 175 |
| 2007 | 172 |
| 2008 | 180 |
| 2009 | 211 |
| 2010 | 152 |
| 2011 | 155 |
| 2012 | 163 |
| 2013 | 25 |
| 2014 | 27 |
| 2015 | 19 |
| 2016 | 29 |
| 2017 | 44 |
| 2018 | 65 |
| 2019 | 81 |
| 2020 | 56 |
| 2021 | 85 |
| 2022 | 67 |
| 2023 | 99 |
| 2024 | 113 |
| 2025 | 38 |
| 2026 | 20 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,788 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| multi-organ failureSignal | 72 | 37.1 | 29.5 | 2,483 |
| convulsionSignal | 188 | 29.3 | 25.5 | 5,100 |
| septic shockSignal | 74 | 15.1 | 12.1 | 962 |
| sepsisSignal | 103 | 8.2 | 6.8 | 647 |
| product use in unapproved indicationSignal | 221 | 7.9 | 7.0 | 1,343 |
| respiratory failureSignal | 59 | 7.2 | 5.6 | 309 |
| thrombocytopeniaSignal | 72 | 5.7 | 4.6 | 277 |
| renal failureSignal | 74 | 4.9 | 4.0 | 230 |
| pneumoniaSignal | 116 | 3.2 | 2.7 | 174 |
| pyrexiaSignal | 122 | 3.1 | 2.6 | 177 |
| rash | 72 | 1.5 | 1.2 | 10 |
| off label use | 115 | 1.2 | 1.0 | 3 |
| death | 91 | 0.9 | 0.8 | 0 |
| drug ineffective | 127 | 0.9 | 0.7 | 3 |
| nausea | 60 | 0.7 | 0.5 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.